Bortezomib for the treatment of acute lymphoblastic leukemia

References

• Pui CH, Yang JJ, Hunger SP, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33:2938–2948.
   PubMed Web of Science ®Google Scholar
• Pui CH, Evans WE. A 50-year journey to cure childhood acute lymphoblastic leukemia. Seminars in Hematology. 2013;50:185–196.
   PubMed Web of Science ®Google Scholar
• Frei E, Bodey GP, Whitecar J, et al. Advances in the chemotherapy of acute leukemia. Bibl Haemat. 1970;36:689–700.
   PubMedGoogle Scholar
• Mehta PS, Wiernikowski JT, Petrilli JAS, et al. Essential medicines for pediatric oncology in developing countries. Pediatr Blood Cancer. 2013;60:889–891.
   PubMed Web of Science ®Google Scholar
• Hitchcock-Bryan S, Gelber R, Cassady JR, et al. The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1986;14:211–215.
   PubMedGoogle Scholar
• Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group study AALL0031. Leukemia. 2014;28:1467–1471.
   PubMed Web of Science ®Google Scholar
• Harned TM, Gaynon P. Relapsed acute lymphoblastic leukemia: current status and future opportunities. Curr Oncol Rep. 2008;10:453–458.
   PubMed Web of Science ®Google Scholar
• Bhatia S, Landier W, Hageman L, et al. Systemic exposure to thiopurines and risk of relapse in children with acute lymphoblastic leukemia: a Children’s Oncology Group Study. JAMA Oncol. 2015;1:287–295.
   PubMedGoogle Scholar
• Rowe JM. Optimal management of adults with ALL. Br J Haematol. 2009;144:468–483.
   PubMed Web of Science ®Google Scholar
• American Cancer Society [Internet]. [cited 2016 May 11]. Available from: http://www.cancer.org/cancer/leukemia-acutelymphocyticallinadults/detailedguide/leukemia-acute-lymphocytic-key-statistics.
   Google Scholar
• Eurostat - Statistics Explained. [cited 2016 May 11]. Available from: http://ec.europa.eu/eurostat/statistics-explained/index.php/File:Population_and_population_density,_1960_and_2012.png.
   Google Scholar
• Brown RE, Bostrom B, Zhang PL. Morphoproteomics and bortezomib/dexamethasone-induced response in relapsed acute lymphoblastic leukemia. Ann Clin Lab Sci. 2004;34:203–205.
   PubMed Web of Science ®Google Scholar
• Kortuem KM, Zidich K, Schuster SR, et al. Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014;14:284–290.
   PubMed Web of Science ®Google Scholar
• Hammack WJ, Huguley CM, Chan YK. Treatment of myeloma – comparison of melphlan, chlorambucil, azathioprine. Arch Intern Med. 1975;135:157–162.
   PubMedGoogle Scholar
• Alberts DS, Durie BG. Salmon SE Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics. Cancer Treat Rep. 1977;61:381–388.
   PubMedGoogle Scholar
• Carbone PP, Frei E, Owens AH, et al. 6-Thioguanine therapy in patients with multiple myeloma. Cancer Chemother Rep. 1964;36:59–64.
   PubMedGoogle Scholar
• Du X, Chen Q. Recent advancements of bortezomib in acute lymphocytic leukemia treatment. Acta Haematol. 2013;129:207–214.
   PubMed Web of Science ®Google Scholar
• Niewerth D, Dingjan I, Cloos J, et al. Proteasome inhibitors in acute leukemia. Expert Review of Anticancer Therapy. 2013;13:327–337.
   PubMed Web of Science ®Google Scholar
• Bose P, Batalo MS, Holkova B, et al. Bortezomib for the treatment of non-Hodgkin’s lymphoma. Expert Opin Pharmacother. 2014;15:2443–2459.
   PubMed Web of Science ®Google Scholar
• Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615–2622.
   PubMed Web of Science ®Google Scholar
• Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6:813–823.
   PubMed Web of Science ®Google Scholar
• Bhadri VA, Trahair TN. Lock RB glucocorticoid resistance in paediatric acute lymphoblastic leukaemia. J Paediatr Child Health. 2012;48:634–640.
   PubMed Web of Science ®Google Scholar
• Chandra J, Niemer I, Gilbreath J, et al. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood. 1998;11:4220–4229.
   Google Scholar
• Horton TM, Gannavarapu A, Blaney SM, et al. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006;58:13–23.
   PubMed Web of Science ®Google Scholar
• Niewerth D, Niels E, Franke NE, et al. Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. Haematologica. 2013;98:1896–1904.
   PubMed Web of Science ®Google Scholar
• Kordes U, Krappmann D, Heissmeyer V, et al. Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia. 2000;14:399–402.
   PubMed Web of Science ®Google Scholar
• Weng AP, Ferrando AA, Lee W, et al. Activating mutations of Notch1 in human T cell acute lymphoblastic leukemia. Science. 2004;306:269–271.
   PubMed Web of Science ®Google Scholar
• Huang C, Hu X, Wang L, et al. Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro. Cancer Chemother Pharmacol. 2012;70:801–809.
   PubMed Web of Science ®Google Scholar
• Vilimas T, Mascarenhas J, Palomero T, et al. Targeting the NF-κB signaling pathway in Notch1-induced T-cell leukemia. Nat Med. 2007;13:70–77.
   PubMed Web of Science ®Google Scholar
• Yu P, Petrus MN, Ju W, et al. Augmented efficacy with the combination of blockade of the Notch-1 pathway, Bortezomib and Romidepsin in a murine MT-1 adult T cell leukemia model. Leukemia. 2015;29:556–566.
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50:37–45.
   PubMed Web of Science ®Google Scholar
• Szczepanek J, Pogorzala M, Konatkowska B, et al. Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia. Anticancer Res. 2010;30:2119–2124.
   PubMed Web of Science ®Google Scholar
• Horton TH, Pati D, Plon SE, et al. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a children’s oncology group study. Clin Cancer Res. 2007;13:1516–1522.
   PubMed Web of Science ®Google Scholar
• Muscal JA, Thompson PA, Horton TM, et al. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children’s Oncology Group phase I consortium study (ADVL0916). Pediatr Blood Cancer. 2013;60:390–395.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, San Miguel JF, Jagannath S, et al. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment. Clin Cancer Res. 2012;18:2145–2163.
   PubMed Web of Science ®Google Scholar
• LoRusso PM, Venkatakrishnan K, Ramesh K, et al. Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin Cancer Res. 2012;18:2954–2963.
   PubMed Web of Science ®Google Scholar
• Cortez J, Thomas D, Koller C, et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res. 2004;10:3371–3376.
   PubMed Web of Science ®Google Scholar
• Messinger Y, Gaynon P, Raetz E, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer. 2010;55:254–259.
   PubMed Web of Science ®Google Scholar
• Messinger YH, Gaynon PS, Sposto R, et al. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: therapeutic advances in childhood leukemia lymphoma (TACL) study. Blood. 2012;120:285–290.
   PubMed Web of Science ®Google Scholar
• Ko RH, Ji L, Barnette P, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol. 2010 Feb 1;28(4):648–654.
   PubMed Web of Science ®Google Scholar
• Horton TM, Lu X, O’Brien MM, et al. Bortezomib reinduction therapy improves response rates in pediatric ALL in first relapse: A Childrens Oncology Group (COG) study (AALL07P1). J Clin Oncol. 31:2013;(suppl; abstr 10003). Available from: http://meetinglibrary.asco.org/content/111816-132
   Web of Science ®Google Scholar
• Kaspers GJL, Niewerth D, Wilhelm B, et al. Phase II study on bortezomib (BTZ) in multiple relapsed or refractory pediatric acute lymphoblastic leukemia (rALL): high response rate with a modestly intensive regimen including BTZ, not related to pharmacokinetics. Blood. 2015;126:2501.
   Google Scholar
• Combination chemotherapy with or without bortezomib in treating younger patients with newly diagnosed T-cell acute lymphoblastic leukemia or stage ii-IV T-cell lymphoblastic lymphoma [Internet]. [cited 2016 May 11]. Available from: ClinicalTrials.gov Identifier NCT02112916. COG trial that should lead to approval of bortezomib in newly diagnosed T-ALL
   Google Scholar
• Hunger SP, Loh ML, Whitlock JA, et al. Children’s Oncology Group’s 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60:957–963.
   PubMed Web of Science ®Google Scholar
• Total therapy for infants with acute lymphoblastic leukemia (ALL) Available from: ClinicalTrials.gov Identifier NCT02553460. A promising novel therapy that includes bortezomib for a disease with a horrible outcome based on sound preclinical laboratory work.
   Google Scholar
• Four drug reinduction with bortezomib for relapsed or refractory ALL or LL in children and young adults [Internet]. [cited 2016 May 11]. Available from: ClinicalTrials.gov. Identifier NCT02535806
   Google Scholar
• Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010;376:2009–2017.
   PubMed Web of Science ®Google Scholar
• International Study for the Treatment of High Risk Childhood ALL (IntReALL HR 2010) [Internet]. [cited 2016 May 11]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000810-12/AT.
   Google Scholar
• Bortezomib and vorinostat in younger patients with refractory or relapsed MLL rearranged hematologic malignancies [Internet]. [cited 2016 May 11]. Available from: ClinicalTrials.gov. NCT02419755
   Google Scholar
• Re-Induction therapy for relapsed pediatric T-cell acute lymphoblastic leukemia or lymphoma [Internet]. [cited 2016 May 11]. Available from: ClinicalTrials.gov. Identifier NCT02518750
   Google Scholar
• Bortezomib and combination chemotherapy in treating patients with relapsed or refractory acute lymphoblastic leukemia [Internet]. [cited 2016 May 11]. Available from: ClinicalTrials.gov. Identifier: NCT01769209
   Google Scholar
• Dewar R, Chen ST, Yeckes-Rodin H, et al. Bortezomib treatment causes remission in a Ph+ ALL patient and reveals FoxO as a theranostic marker. Cancer Biol Ther. 2011;11:552–558.
   PubMed Web of Science ®Google Scholar
• Vundamati D, Bostrom B. Prolonged response in patient with multiply relapsed B-cell acute lymphoblastic leukemia and monosomy-7 to bortezomib, lenalidomide, and dexamethasone. J Ped Hem Onc. Forthcoming 2016.
   PubMedGoogle Scholar
• Richardson PG, Delforge M, Beksac M, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012 Apr;26(4):595–608.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32:1941–1967.
   PubMed Web of Science ®Google Scholar
• Lavoie Smith EM, Li L, Chiang C, et al. Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. J Peripher Nerv Syst. 2015;20:37–46.
   PubMed Web of Science ®Google Scholar
• Gilchrist LS, Tanner L. The pediatric-modified total neuropathy score: a reliable and valid measure of chemotherapy-induced peripheral neuropathy in children with non-CNS cancers. Support Care Cancer. 2013;21:847–856.
   PubMed Web of Science ®Google Scholar
• Giannoccaro MP, Donadio V, Gomis Pèrez C, et al. Somatic and autonomic small fiber neuropathy induced by bortezomib therapy: an immunofluorescence study. Neurol Sci. 2011;32:361–363.
   PubMed Web of Science ®Google Scholar
• Stratogianni A, Tosch M, Schlemmer H, et al. Bortezomib-induced severe autonomic neuropathy. Clin Auton Res. 2012;22:199–202.
   PubMed Web of Science ®Google Scholar
• Zaman F, Menendez-Benito V, Eriksson E, et al. Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice. Cancer Res. 2007;67:10078–10086.
   PubMed Web of Science ®Google Scholar
• Eriksson E, Wickström M, Perup LS, et al. Protective role of humanin on bortezomib-induced bone growth impairment in anticancer treatment. J Natl Cancer Inst. 2014 Mar;106(3):djt459. Doi:10.1093/jnci/djt459. Epub 2014 Mar 1
   PubMedGoogle Scholar
• Mukherjee S, Raje N, Jesse A, et al. Bortezomib induces the differentiation of mesenchymal stem/progenitor cells into osteoblasts, resulting in new bone formation in osteoporotic mice. J Clin Invest. 2008;118:491–504.
   PubMed Web of Science ®Google Scholar
• Study of carfilzomib in combination with dexamethasone, mitoxantrone, PEG-asparaginase and vincristine in children with relapsed or refractory acute lymphoblastic leukemia [Internet]. [cited 2016 May 11]. Available from: ClinicalTrials.gov. Identifier: NCT02303821
   Google Scholar
• Carfilzomib and hyper-CVAD in treating patients with newly diagnosed acute lymphoblastic leukemia or lymphoma [Internet]. [cited 2016 May 11]. Available from: ClinicalTrials.gov. Identifier: NCT02293109
   Google Scholar
• Phase I study of MLN 9708 in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults. Available from: ClinicalTrials.gov. Identifier: NCT02228772
   Google Scholar
• Egbelakin A, Ferguson MJ, MacGill EA, et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;56(3):361–367.
   PubMed Web of Science ®Google Scholar